SeekingAlpha · Aug 28, 2026
Afya Got Some Regulatory Respite But The Education Quality Risk Remains
Afya (AFYA) Q2 2026 update: revenue +6% YoY but margins and student growth slow. ENAMED regulatory risk hits pricing power.
NASDAQ · AFYA
Consumer Defensive · Education & Training Services
$14.29
Down-$0.39 (-2.66%)
Updated Sep 9, 2026, 3:34 AM
SID Score
6.3/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 20 trading sessions · Daily adjusted prices
AFYA closed at $14.29 after 20 trading sessions, up 5.23% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 8, 2026 | $14.68 | $14.7411 | $14.22 | $14.29 | 266.07K |
| Sep 4, 2026 | $14.80 | $14.95 | $14.49 | $14.68 | 278.53K |
| Sep 3, 2026 | $15.00 | $15.125 | $14.69 | $14.73 | 343.46K |
| Sep 2, 2026 | $14.65 | $14.95 | $14.65 | $14.91 | 95.75K |
| Sep 1, 2026 | $14.61 | $14.80 | $14.2503 | $14.58 | 90.59K |
| Aug 31, 2026 | $14.65 | $14.77 | $14.26 | $14.60 | 728.12K |
| Aug 28, 2026 | $14.38 | $14.73 | $14.27 | $14.59 | 117.92K |
| Aug 27, 2026 | $14.43 | $14.515 | $14.24 | $14.31 | 89.89K |
| Aug 26, 2026 | $14.35 | $14.50 | $14.13 | $14.43 | 123.23K |
| Aug 25, 2026 | $14.22 | $14.38 | $14.10 | $14.35 | 72.2K |
| Aug 24, 2026 | $14.33 | $14.54 | $14.01 | $14.22 | 119.82K |
| Aug 21, 2026 | $13.95 | $14.39 | $13.79 | $14.33 | 108.29K |
| Aug 20, 2026 | $13.88 | $14.00 | $13.56 | $13.88 | 128.19K |
| Aug 19, 2026 | $13.66 | $13.93 | $13.52 | $13.88 | 132.19K |
| Aug 18, 2026 | $13.79 | $13.95 | $13.4075 | $13.55 | 136.5K |
| Aug 17, 2026 | $13.84 | $14.2563 | $13.71 | $13.79 | 149.72K |
| Aug 14, 2026 | $13.40 | $13.905 | $13.33 | $13.84 | 174.97K |
| Aug 13, 2026 | $13.74 | $13.77 | $13.37 | $13.41 | 175.53K |
| Aug 12, 2026 | $13.43 | $13.76 | $13.33 | $13.74 | 143.86K |
| Aug 11, 2026 | $13.43 | $13.60 | $13.22 | $13.58 | 169.34K |
The latest Smart Investors Daily articles mentioning AFYA.
AFYA research
Company profile and research snapshot.
Afya Ltd is a medical education group based in Brazil. Its education portfolio has several courses in addition to Medicine, such as Management, Dentistry, Law, Engineering, Nursing, Psychology, and Accounting Sciences, among others. It has three segments; Undergrad provides educational services through undergraduate courses related to medical school, undergraduate health science and other ex-health undergraduate programs, Continuing Education provides medical education, specialization and graduate courses in medicine, delivered through digital and in-person content; and Medical practice solution provides clinical decision, clinical management and doctor-patient relationships for physicians and provide access, demand and efficiency for the healthcare players.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jun 22, 2026 | JP Morgan | Neutral | — |
| Apr 30, 2026 | JP Morgan | Neutral | — |
| Feb 24, 2026 | B of A Securities | Neutral | — |
| Feb 13, 2026 | Morgan Stanley | Underweight | — |
| Jan 16, 2026 | UBS | Neutral | — |
No generated briefing is available yet.
SeekingAlpha · Aug 28, 2026
Afya (AFYA) Q2 2026 update: revenue +6% YoY but margins and student growth slow. ENAMED regulatory risk hits pricing power.
Benzinga · Aug 24, 2026
https://www.sec.gov/Archives/edgar/data/1771007/000129281426004318/ex99-1.htm
Benzinga · Aug 14, 2026
Afya (NASDAQ:AFYA) raises FY2026 sales outlook from $731.710 million-$759.496 million to $750.168 million-$778.656 million vs $781.560 million estimate.
SeekingAlpha · Aug 14, 2026
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.


The latest Smart Investors Daily articles mentioning AFYA.